WebTwenty-six previously treated patients with refractory small cell lung cancer (SCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. Twenty-five patients had prior exposure to cisplatin plus etoposide, and 14 of the 26 patients (54%) had prior therapy wi … WebDr. Harvey Einhorn, MD is a Hematology Specialist in Rockford, IL and has over 40 years of experience in the medical field. He graduated from University of Illinois College of Medicine in 1983. He is affiliated with SwedishAmerican Hospital. His office accepts new patients and telehealth appointments. 5 (10 ratings) Leave a review
Dr. Lawrence Einhorn, MD – Indianapolis, IN Oncology - Doximity
WebDr. Einhorn serves as a clinical assistant professor of medicine at the University of Illinois College of Medicine at Rockford. For more information regarding Dr. Einhorn, please call... WebDr. Einhorn's clinical interests include solid tumor oncology, specifically within the fields of genitourinary and lung cancers. His legacy will forever … tracking465
Dr. Harvey Einhorn, MD – Rockford, IL Oncology - Doximity
WebEinhorn also had a fellowship in oncology at the MD Anderson Hospital Tumor Institute in Houston, TX. He has served on the IU Medical Center faculty since 1971, being named … WebSep 21, 2016 · , Lawrence H. Einhorn, MD Show More See accompanying commentaries on pages 445 and 449 Abstract Full Text PDF Figures and Tables Abstract The introduction of cisplatin combination chemotherapy, 40 years ago, transformed metastatic testicular germ cell tumors from an almost uniformly fatal disease into a model for a curable neoplasm. WebWith my transition to IU, and as the Medical Director of Cardio-Oncology at IU, I have built impactful, collaborative, multi-disciplinary relationships across specialties and collaborations with world leaders in Medical Oncology (Dr. Lawrence H. Einhorn and others) and clinical research (Dr. Lois B. Travis). Dr. tracking abc cargo